Cargando…

Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival

BACKGROUND: To explore possible improvement in the treatment of locally advanced pancreatic carcinoma (LAPC) we performed a randomized, non-comparative phase II study evaluating docetaxel - plus either daily continuous 5 FU or weekly cisplatin concurrent to radiotherapy. We report here the results o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oberic, Lucie, Viret, Frédéric, Baey, Charlotte, Ychou, Marc, Bennouna, Jaafar, Adenis, Antoine, Peiffert, Didier, Mornex, Françoise, Pignon, Jean-Pierre, Celier, Patrice, Berille, Jocelyne, Ducreux, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191360/ https://www.ncbi.nlm.nih.gov/pubmed/21943032 http://dx.doi.org/10.1186/1748-717X-6-124

Ejemplares similares

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial
por: Jacquemier, Jocelyne, et al.
Publicado: (2011)

Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
por: Sadighi, Sanambar, et al.
Publicado: (2006)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

Standards, Options and Recommendations: SOR organising committee: FNCLCC, Paris
Publicado: (2003)

Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines
por: Suetsugu, Tomonari, et al.
Publicado: (2021)

Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation
por: Fu, Jinbo, et al.
Publicado: (2019)

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.
por: Fleming, R. A., et al.
Publicado: (1992)

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
por: De Angelis, Paula M, et al.
Publicado: (2006)

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer
por: Conroy, T, et al.
Publicado: (2010)

5-FU toxicity and nutritional deficiencies.
por: Stenram, U.
Publicado: (1993)

Fluorouracil (5-FU)-induced Cardiomyopathy
por: Thalambedu, Nishanth, et al.
Publicado: (2019)

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure
por: Dolat, Marine, et al.
Publicado: (2020)

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)
por: Nicholson, S, et al.
Publicado: (2013)

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
por: Conroy, T, et al.
Publicado: (2008)

A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP
por: Seike, Junichi, et al.
Publicado: (2011)

Effect of Skimmed Milk on the Absorption and Metabolism of5-Fluorouracil (5-FU) in Animals
por: Ahmad, Maqsood, et al.
Publicado: (2012)

A unique presentation of 5-fluorouracil (5-FU) induced cerebral encephalopathy
por: Naik, Shailendra S, et al.
Publicado: (2020)

Histopathological Spectrum of Soft-Tissue Tumors with Immunohistochemistry Correlation and FNCLCC grading: A North Indian Experience
por: Singh, Hena Paul, et al.
Publicado: (2017)

Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment
por: Anaka, Matthew, et al.
Publicado: (2022)

The 5S rRNA maturase, ribonuclease M5, is a Toprim domain family member
por: Allemand, Frédéric, et al.
Publicado: (2005)

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
por: Lorenzen, S, et al.
Publicado: (2013)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
por: Kim, Stefano, et al.
Publicado: (2017)

Whole transcriptome sequence data of 5-FU sensitive and 5-FU resistant tumors generated in a mouse model of de novo carcinogenesis
por: Iacovides, Demetris, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.
por: Goldberg, J. A., et al.
Publicado: (1988)

Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells
por: Kim, Eun-Ji, et al.
Publicado: (2018)

Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective
por: Sisic, Leila, et al.
Publicado: (2023)

Skeletal Muscle Quality and Quantity Affect Prognosis after Neoadjuvant Chemotherapy with a Triple Regimen of Docetaxel/Cisplatin/5-FU in Patients with Esophageal Cancer
por: Ito, Nobuhito, et al.
Publicado: (2023)

Eukaryotic translation initiation factor 3 subunit G (EIF3G) resensitized HCT116/5-Fu to 5-fluorouracil (5-Fu) via inhibition of MRP and MDR1
por: Yang, Chenggang, et al.
Publicado: (2018)

5-FU-induced cardiac toxicity - an underestimated problem in radiooncology?
por: Steger, Felix, et al.
Publicado: (2012)

The role of GLI1 for 5-Fu resistance in colorectal cancer
por: Zhang, Lining, et al.
Publicado: (2017)

5-FU induced cardiotoxicity: case series and review of the literature
por: Yuan, Cai, et al.
Publicado: (2019)

Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats
por: El-Sayyad, Hassan I, et al.
Publicado: (2009)

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
por: Rao, S, et al.
Publicado: (2005)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
por: Ueno, Makoto, et al.
Publicado: (2020)

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study
por: Pernot, Simon, et al.
Publicado: (2018)

Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study
por: Basso, Valeria, et al.
Publicado: (2019)

Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study
por: Umeki, Yusuke, et al.
Publicado: (2023)

Prediction of Histologic Subtype and FNCLCC Grade by SUVmax Measured on (18)F-FDG PET/CT in Patients with Retroperitoneal Liposarcoma
por: Li, Cheng-Peng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sfak5nuumh8947l957nopp45lc